Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.825 USD | +6.81% | -0.53% | -16.22% |
05-02 | Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos | MT |
05-01 | Malin Corp investee signs agreement with Astellas Pharma | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.22% | 256M | |
+5.19% | 109B | |
+11.13% | 105B | |
-0.38% | 22.25B | |
-11.92% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.17% | 16.85B | |
+3.24% | 13.76B | |
+36.06% | 12.46B |
- Stock Market
- Equities
- PSTX Stock
- News Poseida Therapeutics, Inc.
- HC Wainwright Adjusts Price Target on Poseida Therapeutics to $20 From $15, Keeps Buy Rating